| Literature DB >> 24731793 |
Sergi Vaquer1, Jordi Masip1, Gisela Gili1, Gemma Gomà1, Joan Carles Oliva1, Alexandre Frechette2, Simon Evetts2, Thais Russomano3, Antonio Artigas1.
Abstract
BACKGROUND: Earlobe arterialized capillary blood gas analysis can be used to estimate arterial gas content and may be suitable for diagnosis and management of critically ill patients. However, its utility and applicability in the ICU setting remains unexplored.Entities:
Keywords: Acute respiratory failure; Arterialized; Capillary blood; Emergency medicine; Intensive care medicine; Mechanical ventilation
Year: 2014 PMID: 24731793 PMCID: PMC4003517 DOI: 10.1186/2110-5820-4-11
Source DB: PubMed Journal: Ann Intensive Care ISSN: 2110-5820 Impact factor: 6.925
Demographic and clinical characteristics of study patients
| Male | 40 (72.7%) |
| Age in years | 63 (24 to 83) |
| Arterial hypertension | 23 (41.8%) |
| Diabetes mellitus | 19 (34.5%) |
| Chronic cardiac failure | 4 (7.3%) |
| Severe vasculopathy | 4 (7.3%) |
| Renal insufficiency | 5 (9.1%) |
| Diagnostic at ICU admission | |
| Severe sepsisa | 21 (38.1%) |
| Respiratory failure | 7 (12.7%) |
| Severe trauma | 7 (12.7%) |
| Neurological | 6 (10.8%) |
| Cardiogenic shock | 5 (9.1%) |
| Miscellaneous | 9 (16%) |
| Clinical variables | |
| PEEP (cmH2O) | 7.1 (4 to 12) |
| FiO2 | 0.36 (0.21 to 0.66) |
| Minute volume (L/min) | 9 (5.5 to 19) |
| APACHE II | 18.3 (3 to 34) |
| Mean arterial pressure (mmHg) | 80 (57 to 113) |
| Cardiac index (L/min/m2) | 3.2 (1 to 5.9) |
| Arterial lactate (mg/dl) | 18.7 (6 to 71) |
| Arterial lactate > 22 mg/dl | 10 (18%) |
| Sepsisa | 32 (58.2%) |
| Platelets (× 103/dl) | 226 (54 to 669) |
| Prothrombin time (ratio) | 1.2 (1 to 1.9) |
| Prophylactic anticoagulant | 40 (72.7%) |
| Antiplatelet treatment | 6 (10.9%) |
| Vasoactive treatment | 36 (65.5%) |
| NE | 30 (83.3%) |
| NE dose (μg/kg/min) | 0.49 (0.02 to 3.02) |
| Other vasoconstriction treatment | 3 (8.2%) |
| Inotropic treatment | 5 (13.8%) |
| Vasodilation treatment | 2 (5.5%) |
Data reported as mean (range), except where% is shown in which case values illustrate ‘incidence’. APACHE II, Acute Physiology and Chronic Health Evaluation II score; NE, norepinephrine; PEEP, positive end expiratory pressure.
aFollowing Surviving Sepsis Campaign Guidelines [17].
Precision analysis
| | ||
|---|---|---|
| PO2 | 9.8 (4.2 to 15.8) | 4.3 (1.8 to 9.3) |
| pH | 0.3 (0.2 to 0.4) | 0.1 (0.08 to 0.1) |
| PCO2 | 7.7 (1 to 16.1) | 3.1 (2 to 5.3) |
| Lactate | 13.8 (3.8 to 21.1) | 26.8 (4 to 66.6)a |
CV, coefficient of variation.
aPrecision of in vitro lactate measures improves with increasing lactate concentrations, therefore mean CV should be interpreted accordingly. At blood lactate concentrations > 2 mmol/L/18 mg/dl, CV decreases below 10%.
Figure 1Differences between capillary and arterial measures. Bland-Altman plots evaluating pH, PO2, PCO2 and lactate measure differences between earlobe arterialized capillary blood and arterial blood. X-axis: average arterial measure. Y-axis: mean difference between earlobe arterialized capillary blood samples (EABC®/i-STAT®) and arterial samples (ABL 700®) of each gasometric and lactate measure.
Factors associated with sampling failure
| Age > 65 years | 1.9 | 0.04a | (1 to 3.7) |
| Diabetes mellitus | 1.9 | 0.03a | (1.1 to 3.4) |
| Vasoactive treatment | 2 | 0.06 | (0.9 to 4.5) |
| Vasoconstrictor treatment | 1.7 | 0.09 | (0.8 to 3.5) |
| NE > 0.22 μg/kg/min | 2.4 | 0.02a | (1 to 5.7) |
| Sepsis | 1.4 | 0.26 | (0.7 to 2.7) |
| Lactate > 22 mg/dl | 1.4 | 0.38 | (0.7 to 3) |
| MAP (< 65 or > 90 mmHg) | 0.8 | 0.57 | (0.4 to 1.6) |
| Age > 65 years | 1.6 | 0.05a | (0.99 to 2.6) |
| Diabetes mellitus | 2.4 | 0.17 | (0.7 to 8.2) |
| Vasoactive treatment | 2.5 | 0.17 | (0.7 to 8.9) |
MAP, mean arterial pressure; NE, norepinephrine; OR, odds ratio; RR, relative risk.
aStatistically significant.